ANGPTL3 and type 2 diabetes mellitus: Vupanorsen, an antisense drug to ANGPTL3 mRNA markedly reduced triglycerides (~50%), apo CIII (~60%), remnant cholesterol (~38%), total cholesterol (~19%), non-HDL-cholesterol (~18%), but had more modest effects on plasma apo B (~9%) in subjects with T2DM and hepatic steatosis.